Quick Links
Past Events

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer - Expert Exchanges on Novel Strategies to Personalize Care

Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer - Expert Exchanges on Novel Strategies to Personalize Care

Sunday, June 4, 2017
7:00 PM - 9:00 PM

Hilton Chicago
Salon Ballroom A, Sections 1 & 2, Lower Level
720 S Michigan Avenue
Chicago, IL 60605


There has been a recent deluge of pre-clinical and clinical data pertaining to the potential applications of poly (ADP-ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer. It is crucial for clinicians who treat patients with breast cancer to have a solid understanding of the mechanistic rationale for the use of these medications, in order to optimize their potential application. It is also important for clinicians to be aware of methods that may help to optimize patient selection for potential PARP inhibitor therapy and personalize breast cancer treatment approaches. There are lessons that may be drawn from the clinical data and experience with PARP inhibitor use in the treatment of ovarian cancer; however, there are distinctions that need to be made regarding the application of these lessons to patients with breast cancer. The Medical Crossfire® format of this symposium will feature leading experts in management of patients with breast cancer who will address multiple topics pertaining to the use of PARP inhibitors in the treatment of patients with breast cancer through a combination of didactic presentation and panel discussion. The program will conclude with a discussion of data presented at the 2017 ASCO Annual Meeting, and a question and answer session to allow participants to interact with the faculty to discuss challenges seen in their own practice settings.

Target Audience:

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer will be invited to participate.

Learning Objectives:

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanistic rationale to target PARP in the treatment of cancers
  • Determine current and emerging methods by which testing for germline/somatic mutations can be utilized and translated to the care of patients with breast cancer
  • Detail evolving efficacy and safety data concerning the application of PARP inhibitors in the treatment of ovarian and breast cancers including how this information can inform personalized decision-making and counseling for patients with these tumors and their families
  • Place available evidence on the use of PARP inhibitor strategies in the clinical context of evolving treatment paradigms in the field of breast cancer management

Program Chair

Mark E. Robson, MD
Attending Physician, Clinical Genetics and Breast Medicine Services
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY

Become a Member

Forgot Password?
Calendar of Events
Filter By